Michael Shepard, Ph.D.

Dr. Shepard was appointed as a Scientific Advisor to EXUMA Biotech in May 2020.  At Genentech, he and a team of researchers discovered Herceptin (trastuzumab), the first monoclonal antibody to block a cancer-causing protein, and developed it into a life-saving therapy for women with breast cancer.  In 2019, Dr. Shepard and two other scientists were awarded the Lasker–DeBakery Clinical Medical Research Award, and in 2006, Dr. Shepard and his research team were awarded Harvard Medical School’s Alpert Prize for this work.  He has been a founder or principal in several biotech companies including Canji, Inc., NewBiotics, Receptor Biologix, and Halozyme.  Dr. Shepard is a frequent guest lecturer and has co-authored many peer-reviewed publications and patents.

Dr. Shepard received his undergraduate degree from the University of California, Davis and his Ph.D. from Indiana University, where he was a Damon Runyon Cancer Research Foundation fellow.